Key facts
- It has raised $3.5M; the latest was Seed Round ($3.5M) in Dec 2025.
- Notable investors include Claris Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Haptena Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Haptena Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Haptena Therapeutics
Developer of immunotherapies designed to provide durable treatment options for oncogene-driven cancers. The company offers precision oncology and immune engineering approaches that integrate mechanistic insights into tumor cell adaptation with the synergy of targeted genetic inhibition and immune activation to identify vulnerabilities in oncogenic pathways, enabling patients with genetically defined tumors, such as KRAS-mutant cancers, to benefit from effective and long-lasting therapies.
- Sector
- Healthcare
- HQ
- Turin, Turkey
- Founded
- 2025
- Website
- haptena.com/
- Ownership
- Privately Held (backing)
Haptena Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Haptena Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Haptena Therapeutics in its N-PORT filings yet. We sweep new filings monthly.